Ranbaxy Laboratories has managed to capture about 2.5% market share in the generic Lipitor segment during initial days of its launch in the US.
Watson Pharmaceuticals and Ranbaxy, the two generic drug makers collectively captured 14.60% of US prescription volume of the cholesterol-lowering drug. But the majority of this has gone to Watson Pharma, which launched the drug just two days ahead of Ranbaxy.
More than 9.38 lakh prescriptions for drugs containing Lipitor’s active ingredient, Atorvastatin, were prescribed for the week ended December 2, 2011. About 8 lakh or 85.40% were written for the branded Lipitor.
On November 30, the Indian drug maker had launched its low-cost version of the drug after getting regulatory approvals hours before the scheduled launch date. Lipitor, the original drug is the world's best selling drug with annual sales of $7.89 billion in the US alone.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1619.95 |
| Dr. Reddys Lab | 1315.85 |
| Cipla | 1294.75 |
| Zydus Lifesciences | 927.15 |
| Lupin | 2296.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: